Deep, targeted upcoming-era sequencing has uncovered that subclonal mutations (i.e., All those current in only a fraction of tumor cells) might be detected for all driver genes and are connected to speedy disease progression and lousy outcome.11–13 This is especially relevant for TP53The clinical program of CLL is quite heterogeneous, starting fr